{"id":1042197,"date":"2012-10-07T15:47:52","date_gmt":"2012-10-07T15:47:52","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/longevity-medicine\/trends-in-multiple-sclerosis-therapy-examined-in-new-insightful-firstword-report-published-at-marketpublishers-com.php"},"modified":"2024-08-17T16:55:22","modified_gmt":"2024-08-17T20:55:22","slug":"trends-in-multiple-sclerosis-therapy-examined-in-new-insightful-firstword-report-published-at-marketpublishers-com","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/longevity-medicine\/trends-in-multiple-sclerosis-therapy-examined-in-new-insightful-firstword-report-published-at-marketpublishers-com.php","title":{"rendered":"Trends in Multiple Sclerosis Therapy Examined in New Insightful FirstWord Report Published at MarketPublishers.com"},"content":{"rendered":"<p><p>    New in-demand report &#8220;Therapy Trends: Multiple Sclerosis &#8212; KOL Insight and    Consensus Outlook Modules&#8221; developed by FirstWord has been    recently published by Market Publishers Ltd. The report    states that the most recent clinical trials of a new multiple sclerosis    therapy were launched in Canada.  <\/p>\n<p>    London, UK (PRWEB) October 02, 2012  <\/p>\n<p>    Besides, new therapies are invented. For instance, the most    recent clinical trials of a new therapy were launched in late    September 2012 in Canada.  <\/p>\n<p>    New in-demand report &#8220;Therapy Trends: Multiple    Sclerosis &#8212; KOL Insight and Consensus Outlook Modules&#8221;    developed by FirstWord has been recently published by    Market Publishers    Ltd.  <\/p>\n<p>    Report Details:  <\/p>\n<p>    Title: Therapy Trends: Multiple Sclerosis &#8212; KOL Insight and    Consensus Outlook Modules  <\/p>\n<p>        Published: September, 2012  <\/p>\n<p>        Price: US$ 7,495.00 <a href=\"http:\/\/marketpublishers.com\/report\/medicine_pharmaceuticals_biotechnology\/healthcare_equipment_services\/therapy-trends-multiple-sclerosis-kol-insight-n-consensus-outlook-modules.html\" rel=\"nofollow\">http:\/\/marketpublishers.com\/report\/medicine_pharmaceuticals_biotechnology\/healthcare_equipment_services\/therapy-trends-multiple-sclerosis-kol-insight-n-consensus-outlook-modules.html<\/a>  <\/p>\n<p>    The report provides a comprehensive guide to trends in multiple    sclerosis therapy. It covers historical sales from 2006 through    2011, market majors and drug developers. The study includes    valuable data on current and late-stage pipeline drugs,    comparative clinical trial results. Sales outlook to 2016,    product positioning forecast, market growth expectations as    well as future event mapping can also be found in the research.  <\/p>\n<p>    Report Contents:  <\/p>\n<\/p>\n<p>More here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/news.yahoo.com\/trends-multiple-sclerosis-therapy-examined-insightful-firstword-report-175621290.html;_ylt=A2KJjalWZnBQdioAnWP_wgt.\" title=\"Trends in Multiple Sclerosis Therapy Examined in New Insightful FirstWord Report Published at MarketPublishers.com\" rel=\"noopener\">Trends in Multiple Sclerosis Therapy Examined in New Insightful FirstWord Report Published at MarketPublishers.com<\/a><\/p>\n<p>Source:<br \/><a href=\"http:\/\/www.longevitymedicine.tv\/trends-in-multiple-sclerosis-therapy-examined-in-new-insightful-firstword-report-published-at-marketpublishers-com\/\">http:\/\/www.longevitymedicine.tv\/trends-in-multiple-sclerosis-therapy-examined-in-new-insightful-firstword-report-published-at-marketpublishers-com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>New in-demand report &#8220;Therapy Trends: Multiple Sclerosis &#8212; KOL Insight and Consensus Outlook Modules&#8221; developed by FirstWord has been recently published by Market Publishers Ltd. The report states that the most recent clinical trials of a new multiple sclerosis therapy &hellip; <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/longevity-medicine\/trends-in-multiple-sclerosis-therapy-examined-in-new-insightful-firstword-report-published-at-marketpublishers-com.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246678],"tags":[],"class_list":["post-1042197","post","type-post","status-publish","format-standard","hentry","category-longevity-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1042197"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1042197"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1042197\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1042197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1042197"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1042197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}